Bottom line
What is LYFCX's expense ratio?
LYFCX's expense ratio is 2.41%, or about $241 a year on every $10,000 invested. That is more expensive than 99% of health care sector funds we track (median 0.96%). It has no front-end sales load. Its expense ratio includes a 1% 12b-1 marketing fee.
Updated Jul 28, 2026
LYFCX fee table
| Net expense ratio | 2.41% |
|---|---|
| Gross expense ratio | 3.08% |
| Management fee | 1.25% |
| 12b-1 (distribution) fee | 1% |
| Other expenses | 0.82% |
| Acquired fund fees | 0.01% |
| Fee waiver / reimbursement | -0.67% |
| Max front-end sales load | 0% |
| Max deferred sales charge | 0% |
| Redemption fee | 0% |
Source: Fund prospectus fee table, filed Jul 28, 2026
What LYFCX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| LYFCX | $244 | $888 | $1,557 | $3,346 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 2.41% expense ratio costs roughly $118,200 in lost growth, versus about $53,400 for the median health care sector fund (0.96%).